Tag: technology

Hong Kong, China, June 09, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3e Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, today announced the pricing of up to $7.4 million aggregate principal amount of senior convertible secured notes (the “Notes”) to be issued in three tranches, and accompanying warrants (the “Warrants”), in a private placement (the “Offering”) to an institutional investor (the “Investor”). The Warrants grant the Investor the right to purchase up to certain number of Class A ordinary shares par value $0.0001 per share (“Shares”), equal to 40% of the maximum principal amount of the First Tranche Note divided by the daily volume weighted average price (“VWAP”) prior to the initial closing date of the First Tranche.

CHANDLER, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Mizuho 2025 Technology Conference on Tuesday, June 10, 2025 at 9:45 a.m. (Eastern Time). Presenting for the Company will be Mr. Richard Simoncic, Chief Operating Officer, and Mr. Sajid Daudi, Head of Investor Relations. A live webcast of the presentation will be made available by Mizuho, and can be accessed on the Microchip website at www.microchip.com.

BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM.

Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes